CRISPR RNP patents
Technology platformA core CRISPR RNP patent portfolio, now licensed into research gene-editing services.
FROM PUBLIC EVENTS · 2026-11-18
Early clinical · first deals Extending its gene-editing patent licences into research services, animals and therapeutics. Also seen: Discovery · preclinical
Roles often seen at this stageBD & licensing · Research & development · Regulatory affairs
A company that licenses its CRISPR gene-editing patents and high-precision editing technology to research, therapeutic, animal and plant partners and co-develops with them.
A core CRISPR RNP patent portfolio, now licensed into research gene-editing services.
A next-generation high-precision gene-editing technology with higher targeting accuracy and fewer off-target edits.
An in vivo gene-editing therapy co-developed with Hong Kong-based GenEditBio that lowers Lp(a) for atherosclerotic cardiovascular disease; a non-human primate proof-of-concept study is complete.
Granted Bioneer a non-exclusive licence to its CRISPR RNP patents and added the Sniper 2L line to an existing licence.
Signed a cross-licence with Hong Kong lipid-nanoparticle company GenEditBio to co-develop in vivo gene-editing therapies.
Licensed CRISPR-Cas9 technology to Avinogen for developing new bird varieties.
Official role guide
Observed 2026-11-18
Information from a role guide does not establish a current vacancy.
A brief based on selected official material, not an exhaustive product or vacancy list.